马索罗酚对实验性自身免疫性脑脊髓炎小鼠IL-6、IL-17、TGF-b表达的影响  

NDGA ameliorates experimental autoimmune encephalomyelitis via the regulation of IL-6, IL-17 and TGF-b

作　　者：李彬[1] 张彦博[1] 孔鹏[1] 张静[1] 陈丽萍[1] 郭力[1] 

机构地区：[1]河北医科大学第二医院神经内科,河北省神经病学重点实验室,石家庄050000

出　　处：《中国神经精神疾病杂志》2016年第9期532-536,共5页Chinese Journal of Nervous and Mental Diseases

基　　金：国家自然科学基金资助项目(编号:81100884)

摘　　要：目的观察马索罗酚(nordihydroguaiaretic acid,NDGA)对实验性自身免疫性脑脊髓炎(experimental autoimmune encephalomyelitis,EAE)小鼠IL-6、IL-17、TGF-β表达的影响。方法采用MOG35-55多肽为抗原免疫C57BL/6小鼠制备EAE模型。小鼠随机分成对照组、模型组和治疗组,各组18只。治疗组给予马索罗酚10mg/(kg·d)干预,对照组及模型组给予等量溶剂干预。分别在发病后10 d、20 d进行神经功能评分后取材,采用实时定量PCR方法检测小鼠腰髓和脾组织IL-6、IL-17、TGF-bm RNA表达水平,采用ELISA方法检测脑组织IL-6、IL-17、TGF-b蛋白表达水平。结果模型组与治疗组发病10 d、20 d时神经功能评分为(7.22±1.10)、(4.22±0.97),(2.89±1.05)、(1.33±0.71),差异有统计学意义(P<0.05)。治疗组与模型组比较结果如下。脊髓组织:1IL-6水平发病10 d时(8.54±2.49)、(14.07±3.19),差异有统计学意义(P<0.05);发病20 d时(4.26±1.44)、(4.90±1.24),差异无统计学意义(P>0.05)。2IL-17水平发病10 d时(25.50±11.77)、(47.59±8.01);发病20 d时(10.02±2.99)、(20.14±4.57),差异均有统计学意义(P<0.05)。3TGF-b水平发病10 d时(0.74±0.11)、(0.04±0.01);发病20 d时(1.49±0.30)、(0.59±0.23),差异均有统计学意义(P<0.05)。脑组织(pg/m L):1 IL-6水平发病10 d时(44.58±6.94)、(57.46±7.32);发病20 d时(35.85±9.58)、(51.29±2.09),差异均有统计学意义(P<0.05)。2IL-17水平发病10 d时(515.90±63.10)、(899.89±242.39);发病20 d时(437.71±137.35)、(730.32±139.94),差异均有统计学意义(P<0.05)。3TGF-b水平发病10 d时(170.88±24.69)、(132.85±20.27);发病20 d时(229.59±32.10)、(172.58±16.94),差异均有统计学意义(P<0.05)。脾组织:1 IL-6水平发病10 d时(6.51±1.29)、(19.76±5.85),差异有统计学意义(P<0.05);发病20 d时(3.13±0.78)、(4.14±0.58),差异无统计学意义(P>0.05)。2IL-17水平发病10 d时(2.08±1.19)、(7.50±1.31);发病20 d时(0.67±0.41)、(2.75±0.44),差异均有统计学意义(P<0.05)。3TGObjective To investigate the effects of nordihydroguaiaretic acid （NDGA） on the expression of IL-6, IL-17 and TGF-β in mice with experimental autoimmune encephalomyelitis （EAE）. Methods C57BL/6 mice were immu-nized with MOG35-55 to induce EAE. The 54 mice were randomly and equally divided into control group, model group and treatment group. Mice in treatment group were daily administered with NDGA （10 mg/kg） by intraperitoneal injection following onset of EAE. Mice in control and model groups were daily treated with equivalent vehicle. Real-time PCR was used to detect IL-6, IL-17 and TGF-b mRNA levels in the spinal cord and spleen on day 10 and 20 post treatment. ELI- SA was used to examine IL-6, IL-17 and TGF- b expression levels in the brain. Results The neurological deficit scores were significantly different between EAE group and treatment group on 10 and 20 days （ 7.22±1.10 vs. 4.22±0.97 on 10 day, P〈0.05; 2.89±1.05 vs. 1.33±0.71 on 20 days, P〈0.05）. The level of of IL-6 in spinal cord was significantly different between EAE group and treatment group on 10 day but not on 20 days （8.54±2.49 vs. 14.07±3.19 on 10 days, P〈0.05; 2.89±1.05 vs. 1.33±0.71, P〉0.05）. The level of IL-17 in spinal cord were significantly different between EAE group and treatment group on 10 and 20 days （ 25.50±11.77 vs. 47.59±8.01 on 10 day, P〈0.05; 10.02±2.99 vs. 20.14±4.57 on 20 day, P〈0.05）. The level of TGF-β in spinal cord were significantly different between EAE group and treatment group on 10 and 20 days （0.74±0.11 vs. 0.04±0.01 on 10 day, P〈0.05; 1.49±0.30 vs. 0.59±0.23 on 20 day, P〈0.05）. The level of IL-6 in brain were significantly different between EAE group and treatment group on 10 and 20 days （44.58±6.94 vs. 57.46±7.32 on 10 day, P〈0.05; 35.85±9.58 vs. 51.29±2.09 on 20 day, P〈0.05）. The level of IL-17 in brain were signifi- cantly different between EAE group and treatment group on 10 and 20 days （515.90±63.10 vs. 899.89±242.39 on 10 day, P〈0.0

关 键 词：马索罗酚 实验性自身免疫性脑脊髓炎 白细胞介素6 白细胞介素17 转化生长因子B 

分 类 号：R744.51[医药卫生—神经病学与精神病学]